🇺🇸 FDA
Pipeline program

Methotrexate 2,5 mg film-coated tablets, Simponi 50 mg solution for injection in pre-filled syringe., Hydroxychloroquine sulfate 200mg film-coated Tablets, Cimzia 200 mg solution for injection in pre-filled syringe, Depo-Medrol 80 mg/2 ml Injektionssuspension, Leflunomide Aurobindo 20 mg compresse rivestite con film, Enbrel 50 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Sulfasalazine 500 mg Tablets, Jyseleca 200 mg film-coated tablets, Kenacort

PRIMERA001

Approved small_molecule active

Quick answer

Methotrexate 2,5 mg film-coated tablets, Simponi 50 mg solution for injection in pre-filled syringe., Hydroxychloroquine sulfate 200mg film-coated Tablets, Cimzia 200 mg solution for injection in pre-filled syringe, Depo-Medrol 80 mg/2 ml Injektionssuspension, Leflunomide Aurobindo 20 mg compresse rivestite con film, Enbrel 50 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Sulfasalazine 500 mg Tablets, Jyseleca 200 mg film-coated tablets, Kenacort for Rheumatoid arthritis according to 2010 criteria is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Rheumatoid arthritis according to 2010 criteria
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials